Is the price fair?
What PRGO's price assumes
Today's price asks for −0.68% free cash flow growth a year; over the last three years Perrigo Company plc delivered −10%, the price is ahead of the record.
0.31
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 8.0%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.4%
- Growth the price implies
- −0.68%
Growth the price implies · The price pays for −0.68% free cash flow growth a year for a decade; the business has delivered −10% a year over the last three.
- Price / book
- 0.52
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.52
- EV / EBIToperating margin −37%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 1.09
- Free cash flow, trailing twelve months
- $108M
- Market capitalisation
- $1.34B
- 3-year revenue growth
- −2.9%
- 3-year free cash flow growth
- −10%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #29 of 29 by Smart Score